Tirzepatide (Mounjaro) has a unique ability to activate two different mechanisms the body uses to control insulin secretion and energy balance, according to research led by Duke University Medical Center. The findings suggest this is the first study to use cells from human donors to demonstrate how tirzepatide stimulates insulin secretion, an important action utilised by this drug to lower blood glucose in patients with type 2 diabetes.
"Understanding the potential of drugs that target more than one mechanism opens a whole new world of discovery for better weight-loss and diabetes drugs," said senior author, Dr Jonathan Campbell, associate professor in the departments of Medicine and Pharmacology and Cancer Biology at Duke University School of Medicine, and member of the Duke Molecular Physiology Institute.
Tirzepatide is a receptor agonist, meaning it binds to a certain receptor in cells, triggering a specific action for that cell to carry out. There is a long history of diabetes therapies that target the glucagon-like peptide-1 (GLP-1) receptor. For people with type 2 diabetes, these GLP-1-based drugs restore insulin production and lower blood glucose. The therapies also make people who take the medication feel full longer and reduce appetite, which leads to people dropping weight over time. This has made GLP-1 based therapies very attractive for the treatment of diabetes and obesity.
Tirzepatide is unique in this class of drugs, in that it targets not only the GLP-1 receptor, but also an additional receptor for the glucose-dependent insulinotropic polypeptide (GIP). In theory, this additional receptor gives the drug a broader range of activity inside the body.
However, the GIP receptor has historically been overlooked as a target for metabolic disease, with some people even proposing to block this receptor rather than activate it. This history fed speculation from some in the field that the activity of tirzepatide at the GIP receptor was not important, inferring that tirzepatide worked as a "super" GLP-1 receptor agonist.
Campbell and colleagues originally expected to find that most of the activity of tirzepatide was at the GLP-1 receptor. But in experiments using donated cadaver islet cells, they found that it was the GIP receptor that was indispensable for the insulin secretion that occurred when the islets were stimulated with tirzepatide.
They also found that tirzepatide stimulated the production of glucagon, another islet hormone. GIP stimulates glucagon secretion, while GLP-1 inhibits it. The finding that tirzepatide stimulates glucagon secretion is more evidence that this drug has important activity at the GIP receptor.
"Because our work shows that tirzepatide is a true multi-receptor agonist, and not just a super-GLP-1 receptor agonist, it validates the potential of using single molecules with activity at more than one receptor as a viable approach to treat metabolic disease," added Campbell. "Extending these studies to the cell types that control appetite and body weight should be an important and exciting future direction."
The findings were reported in the paper, ‘The incretin co-agonist tirzepatide requires GIPR for hormone secretion from human islets’, published in Nature Metabolism.
To access this paper, please click here